Group items tagged

The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour. The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone. Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible. "Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease."

The Royal Pharmaceutical Society (RPS) has confirmed that the recall of blood pressure drugs amlodipine and olmesartan by the Food and Drug Administration is only for the US market and will not have any impact in the UK. MHRA also clarified that the manufacturer of these drugs, Macleod Pharmaceuticals, does not supply amlodipine medicines in the UK. It was published online in both the Daily Record and Daily Express on the morning of Monday, March 21, that the drugs had been recalled in the US by the FDA due to deviations from standard manufacturing protocols by the manufacturer. RPS intervened to ensure the articles were edited to make clear that this is not an issue in the UK after confirmation from the MHRA. Amlodipine tablets from Macleod Pharmaceuticals aren't available for wholesale distribution in the UK.

The Health and Social Care Secretary has announced over £175 million funding to boost genomics research in the UK. Through this funding, the government aims to create the most advanced genomic healthcare system in the world. "Patients with cancer and children born with treatable rare genetic diseases are set to benefit from earlier diagnosis and faster access to treatment, following a £175 million boost to cutting-edge genomics research announced by the Health and Social Care Secretary today (Tuesday)," said DHSC. The funding will enable research which could deliver world-leading genomic healthcare to patients, which involves the study of people's DNA. "£105 million to be funded to kickstart a world-leading research study, led by Genomics England in partnership with the NHS, to explore the effectiveness of using whole genome sequencing to find and treat rare genetic diseases in newborn babies," said DHSC. "An initial £26 million to support an innovative cancer programme, led by Genomics England in partnership with the NHS, to evaluate cutting-edge genomic sequencing technology to improve the accuracy and speed of diagnosis for cancer patients and use artificial intelligence to analyse a person's DNA, alongside other information such as routine scans.

The UK Health Security Agency (UKHSA) has suggested that the Live Attenuated Influenza Vaccine (LAIV) vaccine that offers protection to children against flu may also help reduce the rate of group A strep infections. LAIV is a nasal spray offered each season to most children aged 2 and 3 years old, and to school-aged children, to help protect against flu. The new study looked back at data from 2013 to 2017, comparing rates of group A strep (GAS) infections in pilot areas and comparing them to other areas where the vaccine was not being offered as widely. It was found that incidence of GAS was lower in pilot areas where the LAIV vaccine was being offered to all primary school children, compared to areas where it was being incrementally rolled out. The study revealed, in 2 to 4 year olds, rates of GAS were 73.5 per 100,000 children in pilot areas, compared to 93 per 100,000 children in non-pilot areas. In 5 to 10 year olds, rates of GAS were 50.3 per 100,000 children in pilot areas, compared to 57.8 per 100,000 in non-pilot areas.

The Pharmacists' Defence Association (PDA) has undertaken an additional survey of pharmacists employed in the NHS, before deciding to hold their first-ever ballot for industrial action. The PDA has more than 7,000 NHS-employed pharmacists in membership and the union is actively considering balloting those members regarding strike action. The association said: "The experience of some other unions has shown that the government's restrictive rules, designed to make it difficult for working people to lawfully take industrial action, means trade unions should test members' strength of feeling before balloting." "Trade unions are not only forced to rely upon postal ballots, but for lawful industrial action to be taken, the result must also meet three tests- at least 50% of eligible voters must vote; at least 40% of eligible voters must vote 'yes' and a majority of votes must be for 'yes'." The association is asking members in England, Northern Ireland and, Wales to show if their collective wish, insignificant enough strength, is for strike action. PDA has emailed the survey to all its members in the NHS in the three nations and will close on Tuesday 3 January.

There are a lot of different beauty procedures that you can try in order to achieve healthy-looking skin. It's essential to consult with a dermatologist or other skin care professional to find out which procedures will work best for you, depending on your skin type and concerns. This article will briefly describe some of the different procedures that are available. Here are some contemporary beauty procedures to consider. 1. SKIN NEEDLING Skin needling, also known as micro-needling, is a minimally invasive procedure that can be used to improve the overall appearance of your skin. It involves using a device with fine needles to create tiny punctures on the skin's surface. Additionally, the effects of skin needling can last long after the initial treatment, making it a popular choice for those looking for a more lasting solution. This helps to stimulate collagen production and can reduce the appearance of wrinkles, fine lines, scarring, and other skin imperfections. Skin needling can be done independently or with other treatments such as radiofrequency therapy or chemical peels. It's important to note that skin needling should only be performed by a licensed professional. 2. RADIOFREQUENCY THERAPY If you're unhappy with the way your skin looks, it may be time to consider a radiofrequency therapy treatment. Radiofrequency therapy uses electromagnetic waves to heat up the deeper layers of your skin, stimulating collagen production and improving blood circulation. This can help to improve the appearance of wrinkles, fine lines, and sagging skin. Additionally, radiofrequency therapy can also help to improve the appearance of cellulite and stretch marks. It's a relatively safe and non-invasive procedure, and there is little to no downtime.

thx for sharing! i would like to use that

That is good option indeed but I guess with a complex training and suggestions u can temporally get rid of that( here for more info https://betterme.world/articles/does-cellulite-go-away/ ). While there is no guaranteed way to completely eliminate cellulite, there are various methods that can help reduce its appearance. Here are some options: Exercise: Regular exercise can help strengthen and tone muscles, reducing the appearance of cellulite. Healthy diet: Eating a healthy, balanced diet can help reduce the appearance of cellulite. Massage: Massaging the areas with cellulite may help improve circulation and reduce its appearance. Topical treatments: Creams and lotions containing caffeine, retinol, or antioxidants may help reduce the appearance of cellulite. Medical procedures: More invasive procedures such as laser therapy, radiofrequency treatments, and liposuction may also be options for reducing cellulite, but they can be expensive and may come with risks. It's important to remember that cellulite is a natural part of the body and many people have it, regardless of their weight or fitness level. While these methods may help reduce its appearance, it may not completely go away.

The National Health Service (NHS) has said that the roll-out of blood-thinning drugs has helped save thousands of lives. In January 2022, the NHS launched a drive to rapidly expand the use of life-saving direct oral anticoagulants (DOACs) in people who are at increased risk of strokes. Since then, more than 24 million prescriptions have been given to such patients and around 460,000 more people have started taking the drugs. This prevented an estimated 17,000 strokes and 4,000 deaths in the last 18 months, as revealed by the new NHS data. Amanda Pritchard, the NHS chief executive, hailed the "lifesaving NHS rollout" at the King's Fund annual conference. It is part of a major NHS drive on "prevention" - to catch more killer conditions earlier and save more lives.

Long waits for an ambulance or surgery led to the death of 112 people, and nearly 8,000 more people suffered harm while waiting for help in England last year. The data from NHS England, obtained by The Guardian, show that patient deaths arising directly from care delays have risen more than fivefold over the last three years. In 2019, there were 21 patient deaths due to NHS care delays, and 96 people suffered "severe harm" as compared to 152 last year. Adult mental health care was mostly affected with 471 patients experiencing harm due to delays, followed by childbirth care (253), eye problems (221), and trauma and general surgery (207). There has been increase of 97 percent in the overall number of people suffering some degree of harm, from 3,979 in 2019 to 7,856 in 2022.

Following the UK government's new pay offer to NHS consultants, the Royal College of Nursing (RCN) wrote to the Health Secretary Victoria Atkins calling for fresh negotiations about nursing pay in England last week. However, the Department of Health and Social Care (DHSC) has rejected their demand, stating that there is no basis to reopen talks as the pay deal was accepted by the NHS Staff Council. In the previous pay deal, nurses were given a one-off payment between £1,655 and £3,789 for 2022/23, and a 5 per cent consolidated pay increase for the 2023/24 financial year. Nursingnotes quoted a DHSC spokesperson as saying: "We hugely value the hard work of NHS nurses and that is why we provided a 5 per cent pay rise. "We also provided two significant non-consolidated awards, which for nurses at the top of Band 5 was over £2,000, equivalent to an extra 6.1 per cent of their basic pay.

The National Health Service (NHS) retention programme has benefitted 23 NHS Trusts since it launched in April 2022, with thousands fewer staff leaving frontline roles. NHS data showed that 14,000 fewer staff left the service in the 12 months up to August 2023 (108,890) compared to 122,970 the year before. In a statement released on Thursday, the NHS England said it is expanding the pilot programme across the country to benefit 42 more NHS trusts. The programme is part of the NHS Long Term Workforce Plan ambition to retain up to 128,000 more staff over the next 15 years in addition to training record numbers of doctors, nurses and other healthcare professionals. Under this new initiative, NHS staff are being offered extra flexibility with working hours, clinical 'support squads' have been introduced to help menopausal women at work, and HR 'stay advocates' are designated to identify ways to keep staff on the brink of leaving.

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses. Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality. But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.

There were an estimated 408,700 hospital admissions due to smoking in 2022-23, an increase of 4.8 per cent from 389,800 in 2021-22, latest statistics published by NHS England have shown. In 2020-21, there were 314,100 admissions attributed to smoking, which was consistent with fewer hospital admissions overall that year, according to the health service's Statistics on Public Health, 2023 report. However, smoking-related admissions in each of the past three years remained lower than in 2019-20, prior to the Covid pandemic, when there were 446,400 cases. Smoking accounted for around one in six (16 per cent) of all hospital admissions for respiratory diseases last year, eight per cent of all admissions for cancers and seven percent of admissions for cardiovascular diseases.

Drug shortages have become a global issue, with many countries struggling to maintain a consistent supply of common medications, including antidepressants, immunosuppressants and drugs to treat type 2 diabetes and ADHD. Earlier last month, the British Generic Manufacturers Association (BGMA), the trade body for off-patent medicines, warned that 111 products were facing supply problems, the highest on record in the UK, and more than double the number recorded at the start of 2022. More than half of products affected (55) are branded generic drugs, which represent 10 per cent of prescription products used in the UK. The trade body blamed the escalating rebate rate of the government's voluntary scheme for branded medicine pricing and access (VPAS) for these shortages, but Brexit is also cited as another reason for the problem.

The recent industrial action by junior doctors and hospital dental trainees, which is considered the longest strike in NHS history, caused a significant impact on the NHS services. Data published by NHS England showed that 113,779 inpatient and outpatient appointments were rescheduled due to the strike, which began on Wednesday 3 January at 7.00am and finished at 7.00am on Tuesday 9 January. Junior doctors make up around half of all doctors in the health service, but 25,446 staff remained absent from work at the peak of the last week's latest action. The ongoing dispute between junior doctors and government over the 2022/23 pay award has disrupted more than one million hospital appointments so far. The junior doctors' strike in December 2023 impacted 86,329 hospital appointments, and their previous action in October saw over 86,000 appointments cancelled.

In a recent announcement, King Charles has agreed to become a patron of the society at Royal Pharmaceutical Society (RPS) following the footsteps of the late Queen. Buckingham Palace confirmed the news, marking the first anniversary of the Coronation of His Majesty The King and Her Majesty The Queen. This prestigious appointment comes after a meticulous evaluation of over 1000 Patronages, previously held by The late Queen, The former Prince of Wales, and The former Duchess of Cornwall. The decision underscores His Majesty's commitment to supporting organisations dedicated to advancing healthcare and patient well-being. The RPS has a rich history of association with the Royal Family, notably with The late Queen, who served as patron from 1953 until her passing in 2022.

London's Great Ormond Street Hospital and Alder Hey Children's Hospital in Liverpool are poised to introduce groundbreaking gender-related services in England, following the closure of the Gender Identity Development Service (Gids) operated by the Tavistock and Portman NHS Foundation Trust. Amid concerns expressed by hospital executives regarding the closure of Gids, with leaked emails revealing apprehensions about appointment cancellations and inadequate communication with the new services, the National Health Services England (NHSE) has confirmed "its commitment to ensuring continuity of care for patients already accessing endocrine care in GIDS." NHSE's decision to transition to regional services stems from a 2022 interim review, led by Dr. Hilary Cass, which highlighted the need for improved support structures for gender-distressed youth. It emphasized a significant increase in referrals to Gids, surpassing 5,000 in 2021/22, compared to less than 250 a decade ago.

Part of a raft of National Health Services (NHS) measures which aim to support people to prevent or reduce incidence of type 2 diabetes and obesity, the NHS Digital Weight Management Programme has emerged as a beacon of success in the battle against obesity, with a recent study showcasing its effectiveness in aiding weight loss among participants. According to research published in The Obesity Journal, the programme has garnered significant traction, with over 63,000 individuals referred in its inaugural year. Encouragingly, half of those referred opted to enroll in the service, highlighting its appeal and accessibility. Among the 14,000 participants who completed the 12-week programme between April 2021 and March 2022, a notable average weight loss of 3.9kg (equivalent to 8.59lbs) was achieved. Even among those who did not complete the programme, an average weight loss of 2.2kg (approximately 4.85lbs) was observed.

The NHS's latest report on ambulance services in England for March 2024 reveals significant progress in response times for emergency calls across all categories compared to recent months. The Ambulance Quality Indicators (AQI) Statistical Note, released in April, underscores both improvements and persistent challenges within the sector. Recent figures obtained from the Liberal Democratic party suggest ongoing struggles with response times, particularly for category two patients, which may include individuals experiencing strokes or heart attacks requiring a response within 18 minutes. Similarly, in November last year, ambulance waits for category 2 calls surged to their highest level since December 2022, reaching 93 minutes, after dropping to 32 minutes in January 2023 according to the British Heart Foundation. However, according to the latest statistical figures obtained from AQI, March 2024 witnessed the shortest average response times for all four categories of emergency calls since August 2023.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners. The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million. Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt. ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. "While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.